Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celia M Witten

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Stem Cells Translational Medicine|October 24, 2015
Concise Review: The U.S. Food and Drug Administration and Regenerative MedicineCelia M Witten, Richard D McFarland, Stephanie L Simek
The New England Journal of Medicine|December 14, 2016
Clarifying Stem-Cell Therapy's Benefits and RisksPeter W Marks, Celia M Witten, Robert M Califf
Stroke|December 31, 2004
The Food and Drug Administration medical device review process: clearance of a clot retriever for use in ischemic strokeRichard P Felten, Neil R P Ogden, Carlos Peña, et al.
Science Translational Medicine|August 31, 2012
FDA oversight of cell therapy clinical trialsPatrick Au, Deborah A Hursh, Agnes Lim, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Stem Cells Translational Medicine|October 24, 2015
Concise Review: The U.S. Food and Drug Administration and Regenerative MedicineCelia M Witten, Richard D McFarland, Stephanie L Simek
The New England Journal of Medicine|December 14, 2016
Clarifying Stem-Cell Therapy's Benefits and RisksPeter W Marks, Celia M Witten, Robert M Califf
Stroke|December 31, 2004
The Food and Drug Administration medical device review process: clearance of a clot retriever for use in ischemic strokeRichard P Felten, Neil R P Ogden, Carlos Peña, et al.
Science Translational Medicine|August 31, 2012
FDA oversight of cell therapy clinical trialsPatrick Au, Deborah A Hursh, Agnes Lim, et al.
Pageof 1